Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

THE RELATIONSHIP between biologic therapies and the risk of major adverse cardiovascular events (MACEs) and venous ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Akeso (HKEX: 9926) has announced that its new drug application for gumokimab, an IL-17-targeting monoclonal antibody, has ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...

Overall, the marked improvement observed in our patient with PPP suggests that IL-17 inhibitor may be a promising therapeutic option for PPP. However, clinicians should also be aware of the ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.